Ensysce Biosciences (ENSC) Cash & Current Investments (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Cash & Current Investments of $4.3 million for Q4 2025, up 23.08% year-over-year from $3.5 million in Q4 2024, and up 157.61% quarter-over-quarter from $1.7 million in Q3 2025.
Ensysce Biosciences (ENSC) Cash & Current Investments (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Cash & Current Investments for 9 consecutive years, with $4.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash & Current Investments rose 23.08% year-over-year to $4.3 million; the TTM figure through Dec 2025 stood at $4.3 million (up 23.08% YoY), while the FY2025 annual figure was $4.3 million, up 23.08% from the prior year.
- Cash & Current Investments advanced to $4.3 million in Q4 2025 per ENSC's latest filing, from $1.7 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $12.3 million in Q4 2021 and bottomed at $250000.0 in Q1 2021.
- Historically, Cash & Current Investments has averaged $4.3 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2021 — Cash & Current Investments jumped 12697.56% — and 2023, when it tumbled 83.23%.
- Ensysce Biosciences' Cash & Current Investments stood at $12.3 million in 2021, then tumbled by 74.34% to $3.1 million in 2022, then plunged by 64.3% to $1.1 million in 2023, then jumped by 211.68% to $3.5 million in 2024, then climbed by 23.08% to $4.3 million in 2025.
- Business Quant data shows ENSC's Cash & Current Investments at $4.3 million in Q4 2025, $1.7 million in Q3 2025, and $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | 4.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 2.21 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | 4.15 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 3.83 Mn |
| Mar 31, 2023 | 1.42 Mn |
| Dec 31, 2022 | 3.15 Mn |
| Sep 30, 2022 | 4.50 Mn |
| Jun 30, 2022 | 12.09 Mn |
| Mar 31, 2022 | 8.44 Mn |
| Dec 31, 2021 | 12.26 Mn |
| Sep 30, 2021 | 6.85 Mn |
| Jun 30, 2021 | 8.01 Mn |
| Mar 31, 2021 | 250,000.00 |